MedPath

Deferasirox

Generic Name
Deferasirox
Brand Names
Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan
Drug Type
Small Molecule
Chemical Formula
C21H15N3O4
CAS Number
201530-41-8
Unique Ingredient Identifier
V8G4MOF2V9
Background

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication

For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions
Chronic Iron Overload
Associated Therapies
-
Clinical Trials
Related News
pmc.ncbi.nlm.nih.gov
·

Management of Patients with Lower-Risk Myelodysplastic Neoplasms

Myelodysplastic neoplasms (MDS) are clonal hematologic disorders with updated classifications in WHO 2022 and ICC 2022, incorporating genetic data for improved diagnosis and treatment. The International Prognostic Scoring System-Molecular (IPSS-M) enhances risk stratification. Treatments for lower-risk MDS aim to improve cytopenias, with new therapies like luspatercept and decitabine/cedazuridine approved. Ongoing clinical trials explore newer agents, emphasizing personalized therapy based on genetic and morphologic data.

Related Clinical Trials:

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy